Source: http://moviesblog.mtv.com/2012/12/13/garrett-hedlund-tron-3/
angelman syndrome total recall troy tulowitzki katie couric good morning america the rock vs john cena acm awards 2012 january jones
Saturday, December 15, 2012
Garrett Hedlund Confirms Return For 'Tron 3'
By Hannah Soo Park The "Tron: Legacy" sequel may not have an official title yet, but it's just been confirmed that the movie has a star lined up to play one of its leading roles. While doing press for the U.S. release of "On the Road," actor Garrett Hedlund confirmed to NextMovie that he will, [...]
Friday, December 14, 2012
Alzheimer's-plagued Colombia region is focus of drug trial
YARUMAL, Colombia ? The unusually high incidence of early-onset Alzheimer's disease in this isolated cattle town has thrust it to the forefront of global efforts to find a cure for the debilitating malady.
Next spring, 100 residents of this region in northwestern Colombia who are known to carry a mutant gene linked to the disease will begin taking a therapeutic drug produced by the U.S. biotechnology firm Genentech. The five-year clinical trial, called the Alzheimer's Prevention Initiative, will cost $100 million. The effort is backed by the U.S. National Institutes of Health and includes UCLA.
What sets this drug trial apart is that the patients, most of them in their 30s, will begin treatment long before they show symptoms of Alzheimer's. Researchers hope the drug will prevent its onset by blocking or slowing the formation of amyloid plaques in the brain that are associated with the devastating illness.
Because of a rare genetic predisposition among interrelated families, scores of residents here and in surrounding towns are getting Alzheimer's by their late 40s, about 15 years ahead of the norm. The cases can be traced to a "founder effect": a common ancestor's "misspelled" gene, passed down over generations, that makes developing Alzheimer's a virtual certainty.
"It's a heavy burden for the relatives when the victims have to stop working and raising their children at such an early age," said Carlos Orrego, administrator at San Juan de Dios Hospital, Yarumal's biggest. "For the families, the burden can last a very long time."
But the tragic circumstances also make this community an ideal place to test the Genentech drug, called crenezumab, which attacks beta amyloids and prevents them from becoming toxic.
Dr. Francisco Lopera, a co-manager of the trial and a neurologist at the University of Antioquia medical school in Medellin, 80 miles south of here, said it's the first test of its kind to be carried out on apparently healthy people. Lopera confirmed the genetic link to Alzheimer's cases here in the 1980s.
"Anti-amyloid drugs have been used before, but they have failed because they have been taken by patients already suffering from dementia ? in other words, too late," Lopera said. "We are optimistic. We aren't sure it will prevent the disease, but it could delay it for many years, and that's important."
A hundred carriers of the mutant gene will take the drug over five years, and 100 carriers will take a placebo, as will 100 at-risk people who do not have the mutant gene.
A "branch study" also will be conducted at UCLA's Geffen School of Medicine, where researchers have discovered a similar genetic disposition among members of an extended family from Jalisco state in Mexico. As many as 30 who have immigrated to Southern California could take part, neurology professor Dr. John Ringman said.
"It's an exciting and wise investment by the U.S. government in the cutting edge of Alzheimer's research," Ringman said. UCLA is looking for more at-risk patients to participate.
As many as 150 other U.S. patients who are Alzheimer's "mutation carriers" will take part in the trial at a dozen sites, said Dr. Eric Reiman of the Banner Alzheimer's Institute in Phoenix and a co-leader of the project. The inclusion of American patients is important so that Colombians don't feel exploited, he said.
"We think it's important to share benefits and risks with families in the United States," Reiman said.
The Alzheimer's Prevention Initiative is the "cornerstone of the U.S. government's national plan to attack Alzheimer's disease," he said.
The high-stakes research project reflects the growing health threat that Alzheimer's represents. An estimated 5.4 million Americans suffer from the disease, including 1 in 8 Americans older than 65. The percentage will grow in coming years as the population ages.
The cost of treatment and caregiving for Alzheimer's patients is soaring past $200 billion a year, according to the Alzheimer's Assn., providing ample incentive for the government to help find a cure.
To track the drug's progress in inhibiting plaques, patients will receive intravenous injections of a lightly radioactive imaging agent that will bind to amyloids floating in the fluid surrounding the brain. Patients will then undergo periodic brain scans to see whether the amyloid plaques are forming.
Genentech, which spent five years developing crenezumab, is shouldering $65 million of the study's $100-million cost. The NIH and the Banner Alzheimer's Institute are financing the balance.
Richard Scheller, an executive vice president of Genentech, said crenezumab has proved effective in blocking Alzheimer's-like symptoms in laboratory mice.
The trial could also prove or disprove the hypothesis of many researchers that amyloids are at the root of Alzheimer's, which is still a mystery.
"Amyloids are the target," UCLA's Ringman said. "A guaranteed slam-dunk target? No. But it's the best we've got."
Said Scheller: "I've been a scientist a long time and sometimes complicated experiments don't work. But based on encouraging results so far, I'm cautiously optimistic we can help these folks."
Kraul is a special correspondent.
7 layer dip recipe chris carter superbowl 2012 kickoff time what time is the super bowl 2012 nfl mvp lana del rey snl performance nick diaz
Lilly stops rheumatoid arthritis trial for lack of efficacy
(Reuters) - Eli Lilly and Co said it will stop one of three late-stage trials of its rheumatoid arthritis drug tabalumab after an analysis showed that the trial was unlikely to be successful.
The trial was testing the drug in patients with moderate-to-severe rheumatoid arthritis who were not responding adequately to methotrexate therapy, which is a standard rheumatoid arthritis treatment.
The decision was not based on safety concerns, and patients currently enrolled in other tabalumab rheumatoid arthritis studies will continue treatment, Lilly said.
However, the company said it would suspend enrolment of new patients in the rheumatoid arthritis program until additional analysis from other ongoing rheumatoid arthritis studies is completed in early 2013.
"The results of this study were unexpected given the data generated in earlier Phase II clinical studies of tabalumab," Lilly's vice president of autoimmune product development, Eiry Roberts, said.
The discontinuation of the study is expected to result in an after-tax charge of about 2 cents per share in the fourth quarter.
Late-stage trials testing the drug in lupus, an autoimmune disorder, will continue to enroll new patients, the company said.
ISI Group analyst Mark Schoenebaum said the drug's sales were estimated at around $250 million in 2018, noting that rheumatoid arthritis was a competitive market and expectations for the lupus market were low as well.
"If we wipe out all (tabalumab) sales from our model, our discounted cash flow drops about 50 cents, so the impact is small," Schoenebaum added.
The company's shares, which have gained more than 25 percent in the past twelve months, were down 1 percent at $48.50 in afternoon trade on the New York Stock Exchange.
Lilly is working on another rheumatoid arthritis drug called baricitinib, which is being far more closely watched by the industry given its potential. The drug is also getting tested for psoriasis and diabetic nephropathy.
Baricitinib, currently in late-stage development, belongs to a new class of oral medicines called Jak inhibitors that aim to compete with the injected rheumatoid arthritis drugs that currently dominate the market with billions in sales.
Rheumatoid arthritis is an autoimmune disorder that leads to inflammation of the joints and surrounding tissues. Jak inhibitors block enzymes believed to be involved in the inflammatory process.
Pfizer Inc was the first company to bring one of these new drugs to market with the U.S. approval of tofacitinib, which will be sold under the brand name Xeljanz. It was launched last month.
Another autoimmune disorder drug in Lilly's pipeline is ixekizumab ? being tested for psoriasis and psoriatic arthritis.
(Reporting by Esha Dey in Bangalore; Editing by Joyjeet Das)
Source: http://news.yahoo.com/lilly-stop-rheumatoid-arthritis-drug-trial-due-lack-131849121--finance.html
gone tyler perry good deeds pretty in pink nba all star game shark tank john wall gordon hayward
MRS Releases Free White Paper on Reliable Communications ...
Mine Radio Systems, an industry-leading communication and safety solutions provider for the harsh mining environment, has released a free white paper on reliable communications in underground mines.
Following tragic events in many underground mines such as those at the Darby, Alma and Sago coal mines, the need for reliable communications systems in underground mines became evident. These incidents triggered the Mine Improvement and New Emergency Response (MINER) Act of 2006 in the US. The most important aspect of the MINER Act is providing reliable communication for miners before and after tragic incidents.
Click here to download the free white paper entitled 'Wireless Sensor Network in Underground Mines'.
valley fever project x the lorax lorax fisker karma super tuesday states shepard fairey
Thursday, December 13, 2012
New Device Could Help In Battle Against Breast Cancer ? CBS ...
PITTSBURGH (KDKA) ? There could be a breakthrough in the fight against breast cancer.
A new device may help diagnose a common condition after having breast cancer surgery before it becomes a major problem.
Lymph is a clear fluid that drains from the body?s tissues and organs. It contains mostly protein and infection fighting blood cells and it is filtered through lymph nodes.
A swelling called lymphedema can happen if surgery or radiation treatment affects the lymph nodes and vessels. While it?s not life-threatening, it can have a major impact on your quality of life.
Mirtha Richardson is a breast cancer survivor. She underwent a mastectomy, chemotherapy and radiation earlier this year.
?The emotional roller coaster was unbelievable. But, I did well post-operatively. I did very well,? Richardson said.
However, in the months even years after surgery, patients like Richardson still have to worry about developing a condition called lymphedema.
Fluid builds up in the arm after lymph nodes are removed, which restricts motion and causes painful swelling that can be extreme and very noticeable.
Now, doctors at Montefiore Einstein Center for Cancer Care in New York are testing a new device that could pick up early signs of the condition.
The L-Dex uses pads like those used with an EKG. Then, a weak electrical current goes through the arm and measures any increases in fluid.
?The same current you would feel and perceive if you held a double-a battery between two fingers, so it?s truly minimal and it?s imperceptible,? Dr. Lisa Wiechmann said.
If the L-Dex shows there is extra fluid, doctors can begin early treatments, including massage therapy or compression sleeves to keep the condition under control.
Richardson hasn?t show any signs of lymphedema so far.
?I just want to be able to catch it on time. That?s my main concern, be able to catch things on time,? Richardson said.
As part of the study, she?ll be monitored for the next three years.
Currently, doctors use a tape measure to see if there are any changes in the arm after surgery.
RELATED LINKS
More Local News
More Health News
More Reports From Dr. Maria Simbra
Source: http://pittsburgh.cbslocal.com/2012/12/12/new-device-could-help-in-battle-against-breast-cancer/
japan earthquake thursday night football Grammy nominations 2013 Butch Jones Star Trek Into Darkness nhl redskins
Foreclosure Discounts : States To Find The Best Foreclosure Bargains
Mortgage rates and markets change constantly. Stay 100% current by taking The Mortgage Reports by email each day. Click here to get free email alerts, or subscribe to the RSS feed in your browser.
Buying a foreclosed home can be a terrific way to get a "deal". Foreclosed homes typically sell at steep discounts as compared to comparable homes not in foreclosure.
In its latest quarterly report, foreclosure-tracker RealtyTrac shows the states in which foreclosed homes are most deeply discounted.
For real estate investors and first-time buyers, RealtyTrac's data is especially useful.
Click here to see today's mortgage rates.
Foreclosures : 1 In 5 Home Sales Nationwide
Foreclosure-related home sales accounted for 19% of home resales between July-September 2012, according to RealtyTrac's latest?quarterly report. This represents?roughly no change from the quarter prior.
There were 193,000 homes sold in some stage of foreclosure last quarter.
The three stages of foreclosures are Notice of Default, Scheduled Auction, and Bank Repossessions. The former two are known as "pre-foreclosure". The latter is the actual foreclosure event. In Q3 2012, for the first time since five years, the number of homes sold in pre-foreclosure outnumbered those sold by banks.
The average price of a pre-foreclosure home was 27 percent lower than a non-foreclosure residential property last quarter. ?These homes required an average of 359 days to sell after beginning the foreclosure process.
Bank-owned homes, by contrast, sold for an average 38% discount over non-foreclosure homes and required 186 days to sell, on average, after the original date of foreclosure.
Click here to see today's mortgage rates.
Connecticut Leads Foreclosure Discounts
Foreclosure discounts -- like most things in real estate -- are a local phenomenon. Depending on where you live, or where you buy, your discount for buying a distressed home will vary.
Last quarter, the eastern seaboard was the best place to get a foreclosed-home discount. Of the top 10 states in terms of foreclosure discounts, six were located on the East Coast, north of Virginia.
Last quarter's Top 10 states for foreclosure discounts were :
- Connecticut : 46.97% discount over non-foreclosed hoe
- Massachusetts : 46.50% discount over non-foreclosed home
- Ohio : 45.16% discount over non-foreclosed home
- Illinois : 42.90% discount over non-foreclosed home
- Georgia : 42.38% discount over non-foreclosed home
- Maryland : 42.20% discount over non-foreclosed home
- Rhode Island : 42.02% discount over non-foreclosed home
- New Jersey : 41.06% discount over non-foreclosed home
- Kentucky : 40.55% discount over non-foreclosed home
- District of Columbia : 40.16% discount over non-foreclosed home
Interestingly, however, of the three states in which foreclosure sales were most prevalent, none appeared on the "biggest discount list".
In those three states -- Georgia, California, and Arizona -- foreclosure sales accounted for 38%, 36% and 34% of all home resales in Q3 2012.
Click here to see today's mortgage rates.
Buying Foreclosures? Get Pre-Approved.
For buyers of foreclosed homes, it's helpful to have a mortgage pre-approval before making a bid. The foreclosure purchase process can move quickly at times, and it's often good to know you'll be approved for the home for which you're bidding.
This is as true for first-time home buyers using the 3.5% downpayment program via an FHA mortgage as it is for real estate investors planning to use the 5-10 Properties Program. Properties in foreclosure and pre-foreclosure require quick action.
Get started with a mortgage rate quote online.
Click here to see today's mortgage rates.
real life barbie zipper armenian genocide asteroid mining memorial day ivan rodriguez planetary resources
Wednesday, December 12, 2012
Inside David Lynch's Paris art-studio hideaway
PARIS (Reuters) - Behind the doors of a 19th-century printworks in south-central Paris, filmmaker and painter-by-training David Lynch takes a cigarette break after hours of etching abstract shapes and twisted limbs onto stone and wood.
Although best known for dark, surreal movies such as "Eraserhead", "Blue Velvet" and "Mulholland Drive", Lynch was an artist before he began filmmaking and since 2007 has been using the Idem workshop as his studio in Paris, creating some 170 lithographs and engravings.
As three workshop staff clamber onto one of the six giant mechanical presses to print up a fresh design, Lynch - dressed in a blue apron and sporting his trademark white, bouffant hairdo - explains that there is something uniquely inspiring about the Parisian printworks.
"This is totally Parisian. In people's dream of Paris, this place would fit in that dream perfectly," the 66-year-old tells Reuters, speaking above the noise of the whirling cogs and hand-operated cranks that he says remind him of the twisted, industrial world of his debut feature film "Eraserhead".
"Everybody that comes to this place, they feel it...I can feel the past. I can feel the whole art of life going on here."
Artists such as Picasso, Matisse, Chagall and Miro all had their prints produced at the site, a two-floor workshop built in 1880 that is still in use today by artists including Lynch. Encircled by piles of engraving-stones and the odd stuffed toy panther, the presses can also print from digital files.
Lynch's prints - which he says he etches from scratch after "catching" an idea in his mind - vary from Keith Haring-esque red-and-white squiggles and doodles to ghostly Edvard Munch-like humans stranded in desolate landscapes, with titles like "Things In Air Over City" or "Oh, A Bad Dream Comes".
They seem to combine the black-and-white, nightmarish imagery of "Eraserhead" and "The Elephant Man" with the abstract, surreal narratives of Lynch's last two movies, 2001's "Mulholland Drive" and 2006's "Inland Empire".
Lynch has explored other media over the past decade, creating a series of animated shorts posted online called "Dumbland", directing a Duran Duran concert streamed on YouTube and even recording his own solo album called "Crazy Clown Time".
He has even adapted his trademark palette of dark tones and surreal shapes to French tastes, designing a limited edition of Dom Perignon champagne bottles as well as an underground nightclub in the center of Paris called "Silencio".
Despite his obvious enthusiasm for trying out new things, Lynch's affection for Paris comes from its protection of tradition.
"I like the way the French people live. They protect the arts more than any other country," he says. "Here, almost every avenue of life is like an art form."
In a seemingly upside-down world where governments and bankers are suffering from the financial crisis but where big-name artists are fetching higher prices than ever before, Lynch says that he can still separate the urge to make money from the urge to make art.
"It's like Hollywood versus the art way," he says. "I love money for getting things to work and to live. But it's not the reason in my mind to make a film or to make anything."
Asked what his next move is going to be, Lynch says he will continue to work on music and art but adds that there is a movie idea also in the pipeline.
"Music and painting and maybe cinema, but we'll have to wait and see," he says. "Maybe it's going to happen but you need to be deeply in love and, you know...I'm falling in love."
(Reporting by Lionel Laurent, editing by Paul Casciato)
Source: http://news.yahoo.com/inside-david-lynchs-paris-art-studio-hideaway-180453311.html
the flintstones etta james ufc on fox evans vs davis fast times at ridgemont high fast times at ridgemont high soylent green
Subscribe to:
Posts (Atom)